1-13 of 13
Vivek Patel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Patient Distance from Center on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma

Brian Hoeynck, Shakthi Bhaskar, Andrew P Jallouk, Bhagirathbhai Dholaria, Bipin N. Savani, Olalekan O. Oluwole, David Morgan, Salyka M. Sengsayadeth, Adetola A. Kassim, Vivek Patel
Journal: Blood
Blood (2024) 144 (Supplement 1): 3663.
https://doi.org/10.1182/blood-2024-211286
Published: 2024
Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg
Journal: Blood
Blood (2024) 144 (Supplement 1): 4503.
https://doi.org/10.1182/blood-2024-198153
Published: 2024
Journal Articles

Patterns of Use and Impact of Post-Referral and Bridging Therapy on Outcomes in Patients Undergoing CAR T-Cell Therapy for B-Cell Lymphoma: A Single-Center Analysis

Shakthi Bhaskar, Katherine Baker, Danielle Fishman, Spencer Lessans, Bhagirathbhai Dholaria, Reena Jayani, Adetola A. Kassim, Tae Kon Kim, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Salyka Sengsayadeth, Vivek Patel
Journal: Blood
Blood (2023) 142 (Supplement 1): 6940.
https://doi.org/10.1182/blood-2023-186217
Published: 2023
Journal Articles

Impact of Time from Referral to Treatment on Outcomes and Cost of Therapy for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma: An Intention to Treat Analysis

Vivek Patel, Katherine Baker, Danielle Fishman, Spencer Lessans, Trent Morris, Bhagirathbhai Dholaria, Reena Jayani, Adetola A. Kassim, Tae Kon Kim, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Salyka M. Sengsayadeth, Shakthi Bhaskar
Journal: Blood
Blood (2023) 142 (Supplement 1): 5080.
https://doi.org/10.1182/blood-2023-189084
Published: 2023
Journal Articles

Flat Dose Intravenous Immunoglobulin Primary Infection Prophylaxis in Multiple Myeloma Patients on Bispecific Antibody Therapy: Vanderbilt Experience

Naimisha Marneni, Bhagirathbhai Dholaria, Salyka Sengsayadeth, Eden Ayele Biltibo, Vivek Patel, Shakthi Bhaskar, Reena Jayani, Jill Gilbert, Jordan Berlin, Ashwin Kishtagari, Sanjay Mohan, David Morgan, Olalekan O. Oluwole, Bipin N. Savani, Adetola A. Kassim, Muhamed Baljevic
Journal: Blood
Blood (2023) 142 (Supplement 1): 3778.
https://doi.org/10.1182/blood-2023-190749
Published: 2023
Journal Articles

Five Year Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium

Jay Y. Spiegel, Michael D. Jain, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P McGuirk, Abhinav Deol, Kathleen Dorritie, Alison R Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier L. Munoz, Matthew L. Ulrickson, Jason Westin, Julio C. Chavez, Dilan A Patel, Miriam T. Jacobs, Radhika Bansal, N. Nora Bennani, Vivek Patel, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Matthew A Lunning, Saurabh Dahiya
Journal: Blood
Blood (2023) 142 (Supplement 1): 1032.
https://doi.org/10.1182/blood-2023-179868
Published: 2023
Journal Articles

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, Peter A. Riedell, Olalekan O. Oluwole
Journal: Blood
Blood (2022) 140 (Supplement 1): 10971–10973.
https://doi.org/10.1182/blood-2022-155886
Published: 2022
Journal Articles

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole
Journal: Blood
Blood (2022) 140 (Supplement 1): 366–368.
https://doi.org/10.1182/blood-2022-165556
Published: 2022
Journal Articles

Two-Year Landmark Survival Analysis after Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia: An Analysis from the ALWP of the EBMT

Vivek Patel, Myriam Labopin, Thomas Schroeder, Igor Wolfgang Blau, Lars Klingen Gjaerde, Mahmoud Aljurf, Gérard Socié, Urpu Salmenniemi, Wolfgang A Bethge, Jakob Passweg, Marie Balsat, Emma Nicholson, Johanna Tischer, Sebastian Giebel, Zinaida Peric, Eolia Brissot, Bhagirathbhai Dholaria, Bipin B. Savani, Arnon Nagler, Mohamad Mohty
Journal: Blood
Blood (2021) 138 (Supplement 1): 1822.
https://doi.org/10.1182/blood-2021-149821
Published: 2021
Journal Articles

Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura

Brief Report
Jin Yu, Susanne Heck, Vivek Patel, Jared Levan, Yu Yu, James B. Bussel, Karina Yazdanbakhsh
Journal: Blood
Blood (2008) 112 (4): 1325–1328.
https://doi.org/10.1182/blood-2008-01-135335
Published: 2008
Journal Articles

Defective Circulating CD25 Regulatory T Cells in Patients with Chronic Immune Thrombocytopenic Purpura.

Jin Yu, MD, Vivek Patel, BS, Susanne Heck, PhD, Jared Levan, BS, Yu Yu, MD, James B. Bussel, MD, Karina Yazdanbakhsh, PhD
Journal: Blood
Blood (2007) 110 (11): 570.
https://doi.org/10.1182/blood.V110.11.570.570
Published: 2007
Journal Articles

GMA161 Treatment of Refractory ITP: Efficacy of Fcγ-RIII Blockade.

James B. Bussel, MD, Vivek Patel, BS, Cynthia Dunbar, MD, Stephen Lemery, MD, Krista Tibbs, BA, Michael Watts, BA, Daniel Magilavy, MD
Journal: Blood
Blood (2006) 108 (11): 1074.
https://doi.org/10.1182/blood.V108.11.1074.1074
Published: 2006
Journal Articles

Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year.

Vivek Patel, BS, Nino Mihatov, Nichola Cooper, MD, Roberto Stasi, MD, Susanna Cunningham-Rundles, PhD, James B. Bussel, MD
Journal: Blood
Blood (2006) 108 (11): 479.
https://doi.org/10.1182/blood.V108.11.479.479
Published: 2006